| Clinical significance of thyroid incidentalomas identified by 18F-FDG PET/CT: correlation of ultrasonograpy findings with cytology results Ö Demir, N Köse, E Özkan, U Ünlütürk, G Aras, MF Erdogan Nuclear Medicine Communications 37 (7), 715-720, 2016 | 34 | 2016 |
| The association between antibiotic use and survival in renal cell carcinoma patients treated with immunotherapy: a multi-center study DC Guven, R Acar, E Yekeduz, I Bilgetekin, NK Baytemur, C Erol, ... Current Problems in Cancer 45 (6), 100760, 2021 | 16 | 2021 |
| Efficacy of subsequent treatments in patients with hormone-positive advanced breast cancer who had disease progression under CDK 4/6 inhibitor therapy C Karacin, B Oksuzoglu, A Demirci, M Keskinkılıç, NK Baytemür, F Yılmaz, ... BMC cancer 23 (1), 136, 2023 | 11 | 2023 |
| Atezolizumab combined with chemotherapy in the first-line treatment of extensive-stage small cell lung cancer: a real-life data of the Turkish Oncology Group M Gürbüz, Y Kutlu, E Akkuş, EB Köksoy, N Köse, BB Öven, BO Uluç, ... Journal of cancer research and clinical oncology 148 (12), 3547-3555, 2022 | 8 | 2022 |
| The percentage of ALK-positive cells and the efficacy of first-line alectinib in advanced non-small cell lung cancer: is it a novel factor for stratification?(Turkish Oncology … M Hizal, B Bilgin, N Paksoy, MM Atcı, S Kahraman, S Kılıçkap, DC Güven, ... Journal of Cancer Research and Clinical Oncology 149 (8), 4141-4148, 2023 | 4 | 2023 |
| Kanser Hastalarının Ölüm Nedenleri ve Sağkalımı Etkileyen Faktörler M Altınbaş, S Hepşen, İ İmamoğlu, E Sarı, N Köse, F Karataş, B Hacıoğlu, ... Sakarya Tıp Dergisi 5 (1), 5-9, 2015 | 4 | 2015 |
| Treatment efficacy of ribociclib or palbociclib plus letrozole in hormone receptor-positive/HER2-negative metastatic breast cancer S Kahraman, E Erul, M Seyyar, O Gumusay, E Bayram, BC Demirel, ... Future Oncology 19 (10), 727-736, 2023 | 3 | 2023 |
| First-line treatment of patients with HER2-positive metastatic gastric and gastroesophageal junction cancer SA Esen, Y Ergun, C Erol, R Arikan, MM Er, MM Atci, A Topçu, G Uçar, ... Bosnian journal of basic medical sciences 22 (5), 818, 2022 | 3 | 2022 |
| Death Reasons and Factors That Affect on Survival of Cancer Patients M Altınbaş, S Hepşen, İ İmamoğlu, E Sarı, N Köse, F Karataş, B Hacıoğlu, ... Sakarya Tıp Dergisi; Cilt: 5 Sayı: 1; 5-9, 2015 | 2 | 2015 |
| Real-world data on efficacy and safety of first-line alectinib treatment in advanced-stage, ALK-positive non-small-cell lung cancer patients: a Turkish Oncology Group study M Hizal, B Bilgin, N Paksoy, S Kılıçkap, MM Atcı, S Kahraman, ... Future Oncology 18 (23), 2573-2582, 2022 | 1 | 2022 |
| 223P Real-world treatment efficacy of ribociclib or palbociclib plus fulvestrant in hormone receptor-positive/HER2-negative metastatic breast cancer: Turkish Oncology Group … S Kahraman, E Erul, O Gumusay, DC Guven, S Aksoy, G Basaran, ... ESMO Open 9, 2024 | | 2024 |
| Correction: Efficacy of subsequent treatments in patients with hormone-positive advanced breast cancer who had disease progression under CDK 4/6 inhibitor therapy C Karacin, B Oksuzoglu, A Demirci, M Keskinkılıç, NK Baytemür, F Yılmaz, ... BMC cancer 23 (1), 192, 2023 | | 2023 |
| Efficacy of subsequent treatments in patients with hormone-positive advanced breast cancer who had disease progression under CDK 4/6 inhibitor therapy İV BAYOĞLU | | 2023 |
| The percentage of ALK-positive cells and the efficacy of first-line M Hizal, B Bilgin, N Paksoy, MM Atci, S Kahraman, S Kilickap, DC Guven, ... | | 2023 |
| First-line treatment of patients with HER2-positive metastatic gastric and gastroesophageal junction cancer S Akturk Esen, Y Ergun, C Erol, R Arikan, MM Er Association of Basic Medical Sciences of FBIH, 2022 | | 2022 |
| Real-world data on efficacy and safety of first-line alectinib treatment M Hizal, B Bilgin, N Paksoy, S Kilickap, MM Atci, S Kahraman, ... | | 2022 |
| Prognostic factors of perioperative FLOT regimen in operable gastric and C Erol, A Sakin, T Basoglu, E Ozden, D Cabuk, M Dogan, B Oksuzoglu, ... | | 2022 |
| The percentage of ALK-positive cells and the efficacy of first-line alectinib in advanced non-small cell lung cancer: is it a novel factor for stratification?(Turkish Oncology … S Kılıçkap, N Paksoy, B Bilgin, A Sakin, E Özcan, AM Tatlı, M Hızal, ... Springer, 2022 | | 2022 |
| Prognostic factors of perioperative FLOT regimen in operable gastric and gastroesophageal junction tumors: real-life data (Turkish Oncology Group) C Erol, A Sakin, TB TÜYLÜ, E Özden, D Çabuk, M Doğan, ... Turkish Journal of Medical Sciences 52 (4), 1022-1032, 2022 | | 2022 |
| The temporal evaluation of RAS and BRAF mutation by liquid biopsy at progression after bevacizumab combinations in patients with metastatic colorectal cancer (mCRC). I Bilgetekin, M Dogan, C Karacin, FB Basal, E Esin, G Ucar, OA Isak, ... Journal of Clinical Oncology 39 (15_suppl), e15587-e15587, 2021 | | 2021 |
Deniz Can GuvenHacettepe University Internal MedicineVerified email at hacettepe.edu.tr
